Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Metastatic Hepatocellular Carcinoma (HCC)-Pipeline Review, H1 2015

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Metastatic Hepatocellular Carcinoma (HCC)-Pipeline Review, H1 2015', provides an overview of the Metastatic Hepatocellular Carcinoma (HCC)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Metastatic Hepatocellular Carcinoma (HCC)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Metastatic Hepatocellular Carcinoma (HCC) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Metastatic Hepatocellular Carcinoma (HCC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Metastatic Hepatocellular Carcinoma (HCC) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Metastatic Hepatocellular Carcinoma (HCC) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Metastatic Hepatocellular Carcinoma (HCC) Overview 8

Therapeutics Development 9

Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC)-Overview 9

Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC)-Comparative Analysis 10

Metastatic Hepatocellular Carcinoma (HCC)-Therapeutics under Development by Companies 11

Metastatic Hepatocellular Carcinoma (HCC)-Therapeutics under Investigation by Universities/Institutes 12

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline Products Glance 13

Clinical Stage Products 13

Early Stage Products 14

Metastatic Hepatocellular Carcinoma (HCC)-Products under Development by Companies 15

Metastatic Hepatocellular Carcinoma (HCC)-Products under Investigation by Universities/Institutes 16

Metastatic Hepatocellular Carcinoma (HCC)-Companies Involved in Therapeutics Development 17

Active Biotech AB 17

AstraZeneca PLC 18

Celgene Corporation 19

F. Hoffmann-La Roche Ltd. 20

Hutchison MediPharma Limited 21

Kyowa Hakko Kirin Co., Ltd. 22

MedImmune, LLC 23

Mirna Therapeutics, Inc. 24

Novartis AG 25

OncoMed Pharmaceuticals, Inc. 26

Onyx Pharmaceuticals, Inc. 27

Pfizer Inc. 28

Metastatic Hepatocellular Carcinoma (HCC)-Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Target 30

Assessment by Mechanism of Action 32

Assessment by Route of Administration 34

Assessment by Molecule Type 36

Drug Profiles 38

AZD-9150-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

CC-122-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Cell Therapy for Metastatic Hepatocellular Carcinoma-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

codrituzumab-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

dusigitumab-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

erismodegib-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

HMPL-012-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

ipafricept-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

MRX-34-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

oprozomib-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

OSU-2S-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

PF-04518600-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

tasquinimod-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

tivozanib-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

UPO-901-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Metastatic Hepatocellular Carcinoma (HCC)-Recent Pipeline Updates 63

Metastatic Hepatocellular Carcinoma (HCC)-Dormant Projects 82

Metastatic Hepatocellular Carcinoma (HCC)-Discontinued Products 83

Metastatic Hepatocellular Carcinoma (HCC)-Product Development Milestones 84

Featured News & Press Releases 84

Oct 09, 2013: Active Biotech Receives Tasquinimod Milestone Payment from Ipsen for 10TASQ10 Study 84

Jul 30, 2013: Mirna Therapeutics Announces Important Expansion of microRNA Patent Portfolio 84

May 13, 2013: Marina Biotech's Licensee Mirna Therapeutics Initiates Phase I Clinical Trial Of Anticancer Drug MRX34 85

Appendix 86

Methodology 86

Coverage 86

Secondary Research 86

Primary Research 86

Expert Panel Validation 86

Contact Us 86

Disclaimer 87

List of Tables

Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H1 2015 9

Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC)-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Products under Investigation by Universities/Institutes, H1 2015 16

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by Active Biotech AB, H1 2015 17

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by AstraZeneca PLC, H1 2015 18

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by Celgene Corporation, H1 2015 19

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 20

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by Hutchison MediPharma Limited, H1 2015 21

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 22

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by MedImmune, LLC, H1 2015 23

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by Mirna Therapeutics, Inc., H1 2015 24

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by Novartis AG, H1 2015 25

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015 26

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 27

Metastatic Hepatocellular Carcinoma (HCC)-Pipeline by Pfizer Inc., H1 2015 28

Assessment by Monotherapy Products, H1 2015 29

Number of Products by Stage and Target, H1 2015 31

Number of Products by Stage and Mechanism of Action, H1 2015 33

Number of Products by Stage and Route of Administration, H1 2015 35

Number of Products by Stage and Molecule Type, H1 2015 37

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics-Recent Pipeline Updates, H1 2015 63

Metastatic Hepatocellular Carcinoma (HCC)-Dormant Projects, H1 2015 82

Metastatic Hepatocellular Carcinoma (HCC)-Discontinued Products, H1 2015 83

List of Figures

Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H1 2015 9

Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC)-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Products, H1 2015 14

Assessment by Monotherapy Products, H1 2015 29

Number of Products by Top 10 Targets, H1 2015 30

Number of Products by Stage and Top 10 Targets, H1 2015 30

Number of Products by Top 10 Mechanism of Actions, H1 2015 32

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 32

Number of Products by Top 10 Routes of Administration, H1 2015 34

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 34

Number of Products by Top 10 Molecule Types, H1 2015 36

Number of Products by Stage and Top 10 Molecule Types, H1 2015 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Active Biotech AB

AstraZeneca PLC

Celgene Corporation

F. Hoffmann-La Roche Ltd.

Hutchison MediPharma Limited

Kyowa Hakko Kirin Co., Ltd.

MedImmune, LLC

Mirna Therapeutics, Inc.

Novartis AG

OncoMed Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc.

Pfizer Inc.

Metastatic Hepatocellular Carcinoma (HCC) Therapeutic Products under Development, Key Players in Metastatic Hepatocellular Carcinoma (HCC) Therapeutics, Metastatic Hepatocellular Carcinoma (HCC) Pipeline Overview, Metastatic Hepatocellular Carcinoma (HCC) Pipeline, Metastatic Hepatocellular Carcinoma (HCC) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com